Adagene Inc. (ADAG): R&D Expense
$22.03M
Year ended 2025-12-31
-35.3%
3-year compound annual growth
-8.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.03M | -23.4% | 2026-04-01, From 2025-01-01 |
| 2024-12-31 | $28.78M | -21.4% | 2026-04-01, From 2024-01-01 |
| 2023-12-31 | $36.64M | -55.0% | 2026-04-01, From 2023-01-01 |
| 2022-12-31 | $81.34M | +19.4% | 2025-03-24, From 2022-01-01 |
| 2021-12-31 | $68.10M | +103.1% | 2024-03-29, From 2021-01-01 |
| 2020-12-31 | $33.54M | +106.9% | 2023-04-28, From 2020-01-01 |
| 2019-12-31 | $16.21M | +0.8% | 2022-04-26, From 2019-01-01 |
| 2018-12-31 | $16.08M | n/a | 2021-04-28, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Adagene Inc. (ADAG) | 2025-12-31 | $22.03M | -23.4% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $28.53M | -50.4% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $52.65M | +56.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $300.94M | +43.0% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $16.73M | +41.0% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $25.58M | -30.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $90.96M | +78.3% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $681.81M | +23.9% |
| Immunome Inc. (IMNM) | 2025-12-31 | $177.29M | +36.9% |
Compare ADAG, BOLT, ACRS, XENE side by side · Screen every company in Pharmaceutical Preparations ↗